Cargando…

Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre

PURPOSE: To compare the efficacy of eye-drop interferon (IFN) α-2b 1 millionIU/mL with eye-ointment tacrolimus 0.03% in refractory vernal keratoconjunctivitis (VKC). MATERIALS AND METHODS: Fifty patients with VKC refractory to conventional treatment with topical corticosteroids and antihistamines af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Sukriti, Singh, Priyanka, Singh, Mrityunjay, Naik, Mayuresh, Srivastava, Kartikeya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286782/ https://www.ncbi.nlm.nih.gov/pubmed/34285466 http://dx.doi.org/10.2147/OPTH.S322378

Ejemplares similares

Treatment of balanitis of Zoon's with tacrolimus 0.03% ointment
por: Chander, Ram, et al.
Publicado: (2009)

Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis
por: Hazarika, Ajit Kumar, et al.
Publicado: (2015)

Successful Treatment of Recalcitrant Granuloma Gluteale Infantum with Topical Tacrolimus 0.03% Ointment
por: Leung, Alexander K. C., et al.
Publicado: (2021)

Isolated lip dermatitis (atopic cheilitis), successfully treated with topical tacrolimus 0.03%
por: Georgakopoulou, Eleni, et al.
Publicado: (2021)

Childhood chronic anterior uveitis associated with vernal keratoconjunctivitis (VKC): successful treatment with topical tacrolimus. Case series
por: Taddio, Andrea, et al.
Publicado: (2011)

Preoperative COVID-19 Testing for Elective Ophthalmological Procedure in a Tertiary Health Care Centre: Our Experience During the Pandemic
por: Singh, Mrityunjay, et al.
Publicado: (2021)

Kaposi's Varicelliform Eruption During Long-term Treatment of Rosacea with 0.03% Tacrolimus Ointment
por: Chen, Qi-Quan, et al.
Publicado: (2015)

Comparision of efficacy and safety of 0.03% and 0.1% tacrolimus ointment in children with vernal keratoconjunctivitis
por: Saha, Bhawesh Chandra, et al.
Publicado: (2023)

Therapeutic Effect of 0.03% Tacrolimus Ointment for Ocular Graft versus Host Disease and Vernal Keratoconjunctivitis
por: Ryu, Eun Hye, et al.
Publicado: (2012)

Tacrolimus 0.03% ointment for treatment of paediatric lichen sclerosus: a case series and literature review
por: Mazzilli, Sara, et al.
Publicado: (2018)

Therapeutic effects of topical 0.03% Tacrolimus ointment in children with refractory vernal keratoconjunctivitis in Middle East
por: Fiorentini, Sandra Flavia, et al.
Publicado: (2019)

Comparison of topical 0.03% tacrolimus and homologous injectable platelet-rich plasma in the treatment of keratoconjunctivitis sicca in dogs
por: Estanho, Giovana José Garcia, et al.
Publicado: (2023)

Assessment of 5% Amlexanox, 0.1% Triamcinolone Acetonide and 0.03% Tacrolimus in the Management of Oral Lichen Planus
por: AlMutairi, Mohammed, et al.
Publicado: (2023)

308-nm excimer lamp with 0.03% tacrolimus ointment is safe and effective to treat children with non-segmental vitiligo
por: Li, Peishan, et al.
Publicado: (2022)

Safety and efficacy of topical tacrolimus 0.03% in the management of vernal keratoconjunctivitis: a non-randomized controlled clinical trial
por: Eltagoury, Mahmoud, et al.
Publicado: (2022)

P03-003 - Sacroilitis with propionibacterium acnes
por: Galeotti, C, et al.
Publicado: (2013)

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis
por: Carruthers, Jean, et al.
Publicado: (2016)

Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis
por: Bhargava, Rahul, et al.
Publicado: (2019)

LEP Design And Performance For Delta Q = 0.03
por: Keil, Eberhard
Publicado: (1979)

PW03-003 – Altered neutrophil function in PFAPA
por: Sundqvist, M, et al.
Publicado: (2013)

Anticoagulant properties of enoxaparin 400 IU/mL–40 % ethanol catheter lock solution
por: Calvet, Laure, et al.
Publicado: (2015)

Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis
por: Al-Amri, Abdulrahman Mohammed, et al.
Publicado: (2017)

Vascular Endothelial Growth Factor (VEGF) Serological and Lacrimal Signaling in Patients Affected by Vernal Keratoconjunctivitis (VKC)
por: Nebbioso, Marcella, et al.
Publicado: (2018)

Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study
por: Vyas, Prateep, et al.
Publicado: (2011)

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
por: Menzella, Francesco, et al.
Publicado: (2023)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/ml) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis
por: Saini, Vikas, et al.
Publicado: (2018)

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
por: Persu, Cristian
Publicado: (2014)

Pure Stage I Seminoma with an Elevated hCG of 25,265 mIU/ml: A Case Report
por: Katayama, Hiromichi, et al.
Publicado: (2016)

ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL
por: de OLIVEIRA, Valter Oberdan Borges, et al.
Publicado: (2016)

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml
por: Wu, Yingping, et al.
Publicado: (2021)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study
por: Huang, Xu, et al.
Publicado: (2022)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Novel Insights in the Management of Vernal Keratoconjunctivitis (VKC): European Expert Consensus Using a Modified Nominal Group Technique
por: Dahlmann-Noor, Annegret, et al.
Publicado: (2023)

HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
por: Morgan, Jake R., et al.
Publicado: (2021)

Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000–20000 IU/ml with ALT 1–2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT
por: Danis, Nilay, et al.
Publicado: (2021)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_9srbl6fsqnjo58bthjt7v1vs8l